Navigation Links
Enbrelr Enters Safer Zone After Recent Research

Latest studies have declared ENBRELR (etanercept) safe to be used to treat psoriasis up to an extended period of two and half years//. The result of the current studies were presented at the 15th European Academy of Dermatology and Venereology (EADV)Congress . ENBREL is a 'Biologic Medicine which means it is synthesized using recombinant DNA or rDNA derived protein using current principles of biotechnology.

This biologic medicine acts by inhibiting one of the main mediators which triggers off inflammatory processes. Enbrel happens to be topmost biologic therapeutic clinically approved worldwide, It is also less cumbersome for patients as it is marketed in convenient 25mg and 50mg syringes making it most adaptable for treatment purposes.

Bruce Strober MD PhD, co director of the Psoriasis and Psoriatic Arthritis Center at New York University mentions that that these findings are very significant as it confirms the parameters within which Enbrel is safe to be used, and also provides valuable information regarding the use of other biologic medicines as well in the long run.

About 5.1 million people is affected by Psoriasis in U.K alone, according to statistics. The most common type of Psoriasis presents itself in the form of plaques over affected skin surface characterized by thickening of skin which looks reddish with superfluous flaky white scales which fall away on being scratched. Most common symptoms associated with these lesions are severe intolerable itching and redness of skin apart from the drying and scaling away of skin. It is probable that an abnormal response from the immune system of the body cause the skin cells to grow and multiply excessively.

In the 48 week Open Label study that was conducted it was clear that ENBREL produced no unpalatable side effects with extended dosages upto2.5 years when compared with randomized Placebo controlled Parent Studies. No further safety signals were iden tified. These findings support the conclusions derived from previous research done giving ENBREL50mg twice a week in a 96-week study.
MON
'"/>




Related medicine news :

1. More Doctors Suspended As Strike Enters Seventh Day
2. Doctors Strike In Andhra Enters The Second Day
3. Anti-Quota Stir: Stalemate Continues; Fast Enters 10th Day
4. AIIMS Strike Enters Second day, Support Continues To Pour In
5. JIPMER Strike Enters Eighth Day
6. The Food Pyramid Guide Enters Supermarkets
7. Vandetanib Study Enters Third Phase
8. Crucells Rabies MAb Enters Phase I Trial in India
9. Heart Surgery Is Getting Safer for the Old
10. Estrogen Patch is Safer than Pills for Heart
11. Traffic Violations Result in Safer Drivers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: